Hello!

Targeting PTPs via active site has been a long existing problem but not for Jiajun, Jinmin, and Yiming. Congrats on the publication on PTP1B/TCPTP PROTAC! doi.org/10.1002/anie.2…

Had a lot of fun at #ACSSpring2023! Glad to present our research to attendees from around the world and receive the mini grad student from Waters Corporation

Congratulations to Jingmei and Frida for passing the OP! Job well done!

Frederick Nguele Meke defended his thesis on studies of phosphates of regenerating liver (PRLs) and became the first PhD from our lab at Purdue! Congratulations Fred!

Two Ph.D.s in one week! Colin Carlock just defended his thesis on validation of PRL as therapeutic targets using novel animal model systems. Congratulations Dr. Carlock!

Purdue pharmaceutical compound sounds the alarm on cancer cells and unleashes T cells loom.ly/UOtYa04 #pharmacysgiantleap @purdueresfound

Cancer researchers had two years of hard work to synthesize the compound known as TP1L. Could it revolutionize cancer treatment? "It's really a dream come true," said Purdue University professor Zhong-Yin Zhang. I-Team 8 Kody Fisher reports. wishtv.com/news/i-team-8/…

pubs.rsc.org/en/Content/Art… pubmed.ncbi.nlm.nih.gov/37836790/ Two in a row! Check out our recent publications on PROTACs targeting TCPTP and SHP2 as promising cancer treatment!

Check out our new reviews on targeting PTPs as a cancer immunotherapy (bpspubs.onlinelibrary.wiley.com/doi/full/10.11…) and drugging PTPs through targeted protein degradation (…mistry-europe.onlinelibrary.wiley.com/doi/abs/10.100…)!

Yesterday, Brenson Jassim defended his thesis on Design, Structure-Activity Relationships, and Biological Evaluation of Small Molecule PTPN22. Congratulations Dr. Jassim!

Today, Yiming Miao successfully defended his thesis on Drugging the Undruggable Protein Tyrosine Phosphatases, the Expected and Unexpected. Congratulations Dr. Miao!

pleased to share a latest finding from the lab that uncovers an unexpected off-target autophagy blockade by SHP2 allosteric inhibitors that can be exploited for improved treatment of RAS-driven cancers. jci.org/articles/view/…